An update on immune-based alpha-synuclein trials in Parkinson’s disease
Maha Alfaidi, Roger A Barker, Wei-Li Kuan · 2024
Read An update on immune-based alpha-synuclein trials in Parkinson’s disease by Maha Alfaidi, Roger A Barker, Wei-Li Kuan (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11638298.txt.
Description
Maha Alfaidi, Roger Barker, and Wei-Li Kuan review immune trials in Parkinson's disease in this 2024 paper. The disease slowly kills nerve cells that make a key brain chemical. Clumps of a protein called alpha-synuclein are a hallmark of the disease and are tied to its advance, so many therapies aim at those clumps.
The review covers recent trials of vaccines and lab-made antibodies against the protein. Some products aim to provoke the patient's own immune response, while others supply antibodies directly. Results so far are mixed, with varied benefit and some trials stopped early. The authors argue future work must solve those problems to deliver a disease-slowing therapy.
Catalog record
| CREATOR | Maha Alfaidi, Roger A Barker, Wei-Li Kuan |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |